To combat SARS-CoV-2 induced hypercytokinemia and CSS associated with severe COVID-19, inhibitors of pro-inflammatory STAT1 and NF-κB signaling pathways, several anti-inflammatory drugs, and immunomodulatory agents, like, IL-1β, IL-6 antagonists and TNF-α blockers, were widely used to control the infection (Mehta et al., 2020; Ye et al., 2020; Rabaan et al., 2021). The gene discussed is TNF; the disease is COVID-19.